Nathan Edwards is a finance leader with a track record of successfully guiding organizations through critical decisions, fundraising cycles, and periods of growth. He is focused on translating strategic visions into financial realities.

Nathan started as an auditor at Ernst & Young, working across industries including life sciences, technology, and energy. At EY, he supported public and private companies through IPOs, SEC filings, and SOX compliance while developing deep expertise in technical accounting, financial reporting, and internal controls.

Subsequently, at Biogen, he excelled in cross-functional finance and strategy roles working across R&D and Manufacturing, Medical Affairs and Global Commercial, and Corporate Functions. He managed long-term planning, budgeting, and forecasting, and served as a key partner to senior leadership on organizational performance and investment decisions. During his tenure, Nathan supported 8 regulatory filings, closed multiple deals, and expanded Biogen’s global footprint.

After Biogen, Nathan joined Flagship Pioneering as Senior Finance Director, where he provided extensive financial oversight across a portfolio of 13 early-stage biotech companies, supporting budgeting, fundraising, valuation modeling, and operational infrastructure. Later, as VP of Finance at oncology and fibrosis company portfolio company Sonata Therapeutics, he led all financial processes and partnered closely with leadership to assess the financial impact of scientific and operational decisions. He helped extend the company’s financial runway during challenging market conditions and secure Series B and C fundraising to enable preparation for clinical milestones.

Nathan is a graduate of Fairfield University, where he attended on a Division I golf scholarship and earned a Bachelors of Science in Accounting.